The key catalyst is the Phase 2b atopic dermatitis topline data expected in Q1 2027. Cash runway into Q3 2027 provides a buffer, but the company will likely need additional financing before then. Monitor enrollment updates and any early efficacy signals from the ongoing Phase 2b trial.
Drug in focus
TTRX drug pipeline →GX-03
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- ~3-4 years if Phase 2 succeeds; GX-03 needs Phase 3 trials (estimated $55-60M R&D spend per company guidance) and FDA approval. Cash runway only through Q1-Q3 2027, so additional financing likely needed.
- Next catalyst
- None dated
What to watchGX-03 Phase 2 topline data in Q4 2026 is the next binary inflection point. Interim data (June 2026) showed strong efficacy signals (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with zero serious adverse events. The expanded Stage 2 (~120-135 patients) and planned FDA Type-B meeting make Q4 the key catalyst window. Monitor enrollment updates and any competitive landscape shifts from approved topicals (ruxolitinib, roflumilast).
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.79entry
- T+1 · 7d ago +1.33%α +1.70% · $9.92
- T+5 · 17h ago −12.67%α −10.97% · $8.55
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Turn Therapeutics reported a net loss of $6.2M for Q3 2026, wider than the $1.9M loss in Q3 2025, driven by a $3.3M non-cash derivative liability charge. The company highlighted positive Phase 2a data for GX-03 in atopic dermatitis and accelerated its HS trial, but remains a pre-revenue clinical-stage biotech with $10.4M cash funding operations into Q3 2027.
Key Financial Metrics
Key Facts
- Net loss for Q3 2026 was $6.2M ($0.21 per share) vs $1.9M ($0.07) in Q3 2025
- Cash and cash equivalents of $10.4M as of September 30, 2026, expected to fund operations into Q3 2027
- GX-03 Phase 2a atopic dermatitis trial: 59.3% of patients achieved clear/almost clear skin at 4 weeks vs 30.4% vehicle
- Phase 2b atopic dermatitis trial ongoing, topline results expected Q1 2027
- Hidradenitis suppurativa Phase 2a trial accelerated, enrollment to begin Q1 2027
- Robert R. Redfield, M.D., appointed Chief Scientific Officer on September 9, 2026
- R&D expenses increased to $0.6M from $0.2M year-over-year
- G&A expenses decreased to $1.4M from $1.8M year-over-year
- Net loss included $3.3M non-cash charge from change in fair value of derivative liability
Financial Impact
Net loss of $6.2M in Q3 2026, compared to $1.9M in Q3 2025; cash burn rate increased with R&D spending
Risk Factors
- Pre-revenue clinical-stage company with no approved products or revenue stream
- Cash runway only into Q3 2027; additional capital likely needed to complete development
- Phase 2b atopic dermatitis trial results may not replicate Phase 2a findings
- Significant non-cash derivative liability charges may continue to impact reported losses
- Clinical-stage biotech with high volatility and binary trial risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-117180 |
| Document: ea0311399-8k_turn.htm | 0001213900-26-117180 |
| Document: 0001213900-26-117180-index-headers.html | 0001213900-26-117180 |
| Document: 0001213900-26-117180-index.html | 0001213900-26-117180 |
| Document: 0001213900-26-117180.txt | 0001213900-26-117180 |
| 8-K Data (Synthetic) | 0001213900-26-117180 |
Track record
19 reports on TTRX
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +115.10% at T+60 after the May 18, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $8.55 Now $8.55 −0.00% settles Feb 16
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $9.92 Now $8.55 −13.81% settles Feb 8
- Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago S-3 Bearish 6/10 Entry $9.79 Now $8.55 +12.67% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $9.79 Now $8.55 −12.67% settles Feb 5
- Oct 19, 202628d ago DEF 14A Neutral 3/10 Entry $10.47 Now $8.55 −18.34% settles Jan 15
- Oct 6, 20265w ago 8-K Neutral 5/10 Entry $12.10 Now $8.55 −29.34% settles Jan 4
- Sep 10, 20269w ago 8-K Neutral 3/10 Entry $13.38 Now $8.55 −36.10% settles Dec 4
- Sep 9, 20269w ago 8-K Bullish 5/10 Entry $13.75 Now $8.55 −37.82% settles Dec 3
- Aug 18, 202612w ago 8-K Neutral 4/10 Entry $9.99 to $9.92 Now $8.55 −14.41% ▼ −0.70% +1.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers